From the *CHU de Nantes, Psychiatric Neuromodulation Unit, Addictology and Liaison-Psychiatry Department, Nantes University Hospital;
†Laboratory “Movement, Interactions, Performance” (E.A. 4334), Faculty of Sport Sciences, University of Nantes, Nantes;
‡Université de Lyon, Université Claude Bernard Lyon I, EA 4615, Centre Hospitalier le Vinatier, Bron, France;
§CHU de Lyon, Groupement Hospitalier Edouard Herriot, Pavillon N, Service de Psychiatrie des Urgences Lyon, Lyon, France;
∥Department of Physiology, Pharmacology & Neuroscience, Sophie Davis School of Biomedical Education, City University of New York, NY;
¶Division of Experimental Therapeutics, Department of Psychiatry, Columbia University/New York State Psychiatric Institute, New York, NY;
#EA 4275 SPHERE bioStatistics, Pharmacoepidemiology and Human sciEncesREsearch, Faculties of Medicine and Pharmaceutical Sciences, Nantes University;
**CHU de Nantes, CIC0004, Nantes & Université de Nantes, UFR Médecine, Nantes;
††CNRS, Cermes3, Research Center on Sciences, Health, Mental Health and Society, Paris, France; and Departments of
‡‡Advanced Biomedical Sciences and
§§Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples Federico II, Naples, Italy.
Received for publication November 8, 2017; accepted April 26, 2018.
Reprints: Giordano D'Urso, MD, Via Pansini N.5, Edificio 18, 80131 Napoli, Italy (e-mail: [email protected]).
G.d.U. has participated in speaker educational activity (CME) with unrestricted grant from Otsuka; A.B. has received unrestricted grants from Lundbeck Italia and Otsuka Italia for preclinical studies; acted as paid consultant in advisor boards for Takeda, Otsuka, Janssen, and Lundbeck; and received honoraria as speaker for unrestricted CMEs supported by Chiesi, Takeda, Otsuka, Lundbeck, FB Health, and Janssen. The remaining authors have no conflicts of interest or financial disclosures to report.
